## Hessam Kakavand

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9589790/publications.pdf

Version: 2024-02-01

8 880 8 8 papers citations h-index g-index

9 9 9 1760 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. JAMA - Journal of the American Medical Association, 2021, 325, 1620.	7.4	515
2	Recent Randomized Trials of Antithrombotic Therapy for PatientsÂWithÂCOVID-19. Journal of the American College of Cardiology, 2021, 77, 1903-1921.	2.8	150
3	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thrombosis and Haemostasis, 2022, 122, 131-141.	3.4	55
4	Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). Journal of Cardiovascular Pharmacology, 2020, 75, 359-367.	1.9	53
5	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. Journal of the American College of Cardiology, 2021, 78, 1635-1654.	2.8	42
6	Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective. Cardiovascular Drugs and Therapy, 2021, 35, 249-259.	2.6	33
7	Use of novel antithrombotic agents for COVIDâ€19: Systematic summary of ongoing randomized controlled trials. Journal of Thrombosis and Haemostasis, 2021, 19, 3080-3089.	3.8	13
8	Pharmacologic Prevention of Myocardial Ischemia–Reperfusion Injury in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Journal of Cardiovascular Pharmacology, 2021, 77, 430-449.	1.9	12